Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Treatment or prevention of hypokalemia in patients unable to take oral potassium,Maintenance of electrolyte balance in parenteral nutrition
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 m Eq/hour of potassium and a maximum concentration of 40 m Eq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 m Eq per day for mild depletion.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance.
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Potassium is primarily excreted unchanged by the kidneys; not metabolized. Dextrose is metabolized via glycolysis and oxidative phosphorylation.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Potassium is not significantly bound to plasma proteins. Less than 2% of serum potassium is protein-bound; the remainder is free and ionized. There is no specific binding protein; any minimal binding is nonspecific to albumin and globulins.
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
Apparent volume of distribution (Vd) of potassium is large, approximately 0.5-0.6 L/kg for total body potassium, but this reflects distribution into total body water. Exchangeable potassium Vd is about 0.4 L/kg. The Vd for extracellular potassium is only about 0.05 L/kg. Clinically, Vd is not used for dosing because most potassium is intracellular; changes in serum concentration do not predict total body stores well.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
Intravenous: 100% bioavailability. Oral: Solid dosage forms have bioavailability >90% for immediate-release; enteric-coated formulations may have reduced bioavailability (70-80%) due to variability in dissolution and absorption. Liquid formulations approach 100% bioavailability. Absorption occurs throughout the small intestine via passive and active transport; bioavailability is affected by gastrointestinal motility and mucosal integrity.
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
GFR 10-50 m L/min: use with caution and reduce dose by 25-50%; monitor serum potassium closely. GFR <10 m L/min: avoid use unless severe hypokalemia with close monitoring; dose reduction of 50-75% recommended.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25% and monitor potassium. Child-Pugh C: reduce dose by 50% and monitor potassium carefully due to risk of hyperkalemia from decreased hepatic clearance.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
Intravenous infusion at 0.5-1 m Eq/kg/day of potassium, maximum concentration 40 m Eq/L, rate not exceeding 0.5-1 m Eq/kg/hour; adjust based on serum potassium and clinical response.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Lower initial doses recommended (e.g., 10-20 m Eq/day) due to age-related decline in renal function; infuse at rate ≤5 m Eq/hour; monitor serum potassium and renal function closely.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
None
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Risk of hyperkalemia leading to cardiac arrhythmias, especially in patients with renal impairment or receiving potassium-sparing diuretics,Extravasation can cause tissue necrosis,Monitor serum potassium, glucose, and renal function,Use with caution in patients with heart disease or conditions predisposing to hyperkalemia,High concentration infusions require central line administration
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Concurrent use of potassium-sparing diuretics or ACE inhibitors without close monitoring,Conditions causing potassium retention (e.g., severe burns, Addison's disease),Hypersensitivity to potassium chloride or dextrose
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, tomatoes) may increase risk of hyperkalemia. Avoid potassium-containing salt substitutes. No specific food restrictions when used as directed, but dietary potassium should be considered in renally impaired patients.
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
Potassium chloride and dextrose are not teratogenic. Potassium is essential for fetal development; however, hyperkalemia or hypokalemia may cause fetal arrhythmias or growth restriction. Dextrose at 5% is non-teratogenic but maternal hyperglycemia may increase risk of fetal macrosomia or neonatal hypoglycemia.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Potassium chloride and dextrose are normal blood constituents; breastfeeding is safe. M/P ratio not available; potassium levels in milk are regulated within normal range.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
Pregnancy increases plasma volume and GFR, reducing serum potassium slightly. No dose adjustment needed for potassium replacement if hypokalemia is corrected empirically. Dextrose 5% provides 5 g/100 m L; consider if maternal glucose intolerance or gestational diabetes present.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
This solution provides a low concentration of potassium (0.037% = 5 m Eq/L) in dextrose 5%. It is used for maintenance hydration and to prevent hypokalemia in patients with normal renal function. Avoid use in patients with severe renal impairment, hyperkalemia, or conditions causing potassium retention. Monitor serum potassium, glucose, and renal function during infusion. The low potassium concentration may not be sufficient for repletion in significant potassium deficits.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
This medication is given intravenously to maintain fluid and potassium levels. Report any discomfort, swelling, or redness at the IV site.,Avoid potassium-rich foods or supplements unless directed by your healthcare provider.,Tell your doctor if you have kidney problems, heart conditions, or if you are taking potassium-sparing diuretics or ACE inhibitors.,Inform your doctor if you experience muscle weakness, numbness, tingling, or irregular heartbeat.,Do not stop the infusion suddenly without medical advice.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10%, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.. CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 m Eq/hour of potassium and a maximum concentration of 40 m Eq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 m Eq per day for mild depletion.. The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. Potassium is essential for fetal development; however, hyperkalemia or hypokalemia may cause fetal arrhythmias or growth restri. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.